NAGIREDDY PUTLURI to Metabolomics
This is a "connection" page, showing publications NAGIREDDY PUTLURI has written about Metabolomics.
Connection Strength
3.263
-
Recent advances in the metabolomic study of bladder cancer. Expert Rev Proteomics. 2019 04; 16(4):315-324.
Score: 0.481
-
A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women. Cancer Prev Res (Phila). 2019 04; 12(4):237-246.
Score: 0.479
-
Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. Cancer. 2019 03 15; 125(6):921-932.
Score: 0.476
-
Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011 Dec 15; 71(24):7376-86.
Score: 0.289
-
Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One. 2011; 6(7):e21417.
Score: 0.284
-
Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer. JCI Insight. 2024 Sep 10; 9(17).
Score: 0.177
-
DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. Carcinogenesis. 2019 11 25; 40(11):1332-1340.
Score: 0.127
-
Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene. 2020 10; 39(40):6265-6285.
Score: 0.124
-
Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival. Cancer Epidemiol Biomarkers Prev. 2019 04; 28(4):770-781.
Score: 0.119
-
Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl Res. 2018 05; 195:25-47.
Score: 0.111
-
Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget. 2015 Oct 13; 6(31):31997-2012.
Score: 0.095
-
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402.
Score: 0.086
-
Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014 Feb 07; 13(2):1088-100.
Score: 0.084
-
Metabolic landscape in bladder cancer. Curr Opin Oncol. 2025 May 01; 37(3):259-266.
Score: 0.046
-
Identification of distinct stool metabolites in women with endometriosis for non-invasive diagnosis and potential for microbiota-based therapies. Med. 2025 Feb 14; 6(2):100517.
Score: 0.044
-
Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer. Br J Cancer. 2022 03; 126(4):615-627.
Score: 0.036
-
Development of a rational strategy for integration of lactate dehydrogenase A suppression into therapeutic algorithms for head and neck cancer. Br J Cancer. 2021 05; 124(10):1670-1679.
Score: 0.035
-
miR-30a targets gene networks that promote browning of human and mouse adipocytes. Am J Physiol Endocrinol Metab. 2020 10 01; 319(4):E667-E677.
Score: 0.033
-
Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis. Blood. 2020 03 12; 135(11):845-856.
Score: 0.032
-
Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors. Acta Neuropathol Commun. 2018 08 31; 6(1):85.
Score: 0.029
-
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila). 2017 Oct; 10(10):588-597.
Score: 0.027
-
Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. J Urol. 2016 06; 195(6):1911-9.
Score: 0.024
-
EMT-induced metabolite signature identifies poor clinical outcome. Oncotarget. 2015 Dec 15; 6(40):42651-60.
Score: 0.024